Exhibit 99.1
 
concertimage8ka08.jpg
NEWS RELEASE


For additional information contact:
Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
(781) 674-5284
ir@concertpharma.com

Kathryn Morris (media)
The Yates Network
(914) 204-6412
kathryn@theyatesnetwork.com

FOR IMMEDIATE RELEASE

Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update
-- Clinical Programs Advance with CTP-543 Phase 2a Topline Data in Alopecia Areata and CTP-692 Phase 1 Trial Initiation Expected in the Fourth Quarter of 2018 --
-- Conference Call Scheduled Today at 8:30 a.m. EDT --

Lexington, MA (August 2, 2018) -- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2018

“Our focus in the first half of this year has been to execute on advancing our proprietary pipeline candidates to key clinical inflection points. The Phase 2 trial evaluating the 4 and 8 mg twice daily cohorts of CTP-543 for alopecia areata is on track for clinical completion later this year with a topline data readout in the fourth quarter,” said Roger D. Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “In addition, our team is poised to move our next candidate, CTP-692 for schizophrenia, into Phase 1 evaluation by year-end. Importantly, both of these candidates are expected to advance in Phase 2 trials in 2019 in support of their respective registration programs.”

Recent Business Highlights and Upcoming Milestones

CTP-543 Phase 2a Topline Data Expected in the Fourth Quarter of 2018. In the second quarter of 2018, Concert completed enrollment of the 8 mg cohort in its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. The double-blind, randomized, placebo-controlled, sequential dose trial is designed to evaluate the safety and efficacy of 4 mg and 8 mg of CTP-543 twice daily. The primary outcome measure will utilize the severity of alopecia tool (SALT) after 24 weeks of dosing. Topline data from the 4 mg and 8 mg twice daily cohorts is expected in the fourth quarter of 2018.






CTP-543 Protocol Amendment Planned. An independent Data Monitoring Committee (DMC) will conduct a planned safety data review of the second cohort of the CTP-543 Phase 2a trial following 12 weeks of dosing with 8 mg of CTP-543 or placebo twice daily. Pending a positive assessment by the DMC, the Company will propose to the U.S. Food and Drug Administration (FDA) a protocol amendment to also evaluate 12 mg of CTP-543 compared to placebo twice daily. Any amendment to the existing protocol will not impact the planned data readout of the 4 mg and 8 mg twice daily cohorts in the fourth quarter of 2018.

CTP-692 Phase 1 Trial Planned to Begin in the Fourth Quarter of 2018. The Company intends to advance CTP-692 into Phase 1 clinical testing by year-end 2018. The Phase 1 program will include a crossover pharmacokinetic comparison of CTP-692 to d-serine and single and multiple ascending doses of CTP-692. Initial Phase 1 topline data is expected in the first quarter of 2019.

CTP-692 Preclinical Findings to be Presented at ACT 2018. Concert’s preclinical studies have demonstrated that selective deuterium modification increased d-serine exposure and resulted in no changes in creatinine and blood urea nitrogen. These results support CTP-692’s potential to improve the safety profile of d-serine. These findings will be presented as a poster at the American College of Toxicology 2018 Annual Meeting being held November 4-7, 2018.

New Corporate Headquarters. Concert has leased office and laboratory space located at 65 Hayden Avenue, Lexington, Massachusetts for the Company’s new headquarters. Effective August 13, 2018, Concert will occupy the new space. The Company’s existing lease expires in September 2018.

Second Quarter 2018 Financial Results
Cash and Investment Position. Cash, cash equivalents and investments as of June 30, 2018, totaled $180.3 million as compared to $203.2 million as of December 31, 2017.  Concert expects its cash, cash equivalents and investments as of June 30, 2018 to be sufficient to fund the Company into 2021 under its current operating plan.

Revenues. Revenue was $2,000 for the quarter ended June 30, 2018, compared to $15,000 for the same period in 2017.  For the six months ended June 30, 2018, revenue was $10.5 million, compared to $35,000 for the six months ended June 30, 2017.  The increase in revenue in the first half of 2018 relates primarily to non-cash consideration received from Processa Pharmaceuticals in the first quarter of 2018 under a license agreement whereby Processa has worldwide rights to develop and commercialize CTP-499.

R&D Expenses. Research and development expenses were $8.9 million for the quarter ended June 30, 2018, compared to $7.3 million for the same period in 2017. For the six months ended June 30, 2018, R&D expenses were $17.5 million compared to $15.5 million for the same period in 2017. The increase in R&D expenses relate primarily to activities associated with the ongoing CTP-543 Phase 2 clinical trial and increased expense associated with the advancement of CTP-692 in 2018 as a new development program.

G&A Expenses. General and administrative expenses were $5.5 million for the quarter ended June 30, 2018, compared to $5.7 million for the same period in 2017.  For the six months ended June 30, 2018, G&A expenses were $11.1 million compared to $11.0 million for the same period in 2017.  The changes in G&A expenses reflect higher stock compensation in 2018 partially offset by lower professional fees in 2018.

Net Loss. For the quarter ended June 30, 2018, net loss applicable to common stockholders was $13.3 million, or $0.57 per share, compared with a net loss applicable to common stockholders of $13.0 million, or $0.58 per share, for the quarter ended June 30, 2017.






Conference Call and Webcast
The Company will host a conference call and webcast today at 8:30 a.m. EDT to provide an update on the company and discuss second quarter financial results. To access the conference call, please dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International) five minutes prior to the start time.
A live webcast of the second quarter financial results may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for three months.

- Financial Tables to Follow -






Concert Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
 
 
Three Months Ended June 30,
 
Six Months Ended 
 June 30,
 
2018

2017
 
2018
 
2017
Revenue:



 
 
 
 
License and research and development revenue
$
2


$
15

 
$
10,481

 
$
35

Operating expenses:



 
 
 
 
Research and development
8,862


7,285

 
17,518

 
15,522

General and administrative
5,514


5,707

 
11,144

 
10,960

Total operating expenses
14,376


12,992

 
28,662

 
26,482

Loss from operations
(14,374
)

(12,977
)
 
(18,181
)
 
(26,447
)
Investment income
660


155

 
1,300

 
292

Interest and Other expense

 
(205
)
 

 
(205
)
       Unrealized gain (loss) on marketable equity securities
669



 
(627
)
 

Loss before tax provision
(13,045
)

(13,027
)
 
(17,508
)
 
(26,360
)
Provision for income taxes
280

 

 
280

 

Net Loss
$
(13,325
)
 
$
(13,027
)
 
$
(17,788
)
 
$
(26,360
)
 





 
 
 
 
Net loss per share applicable to common stockholders — basic and diluted
$
(0.57
)

$
(0.58
)
 
$
(0.76
)
 
$
(1.17
)
Weighted-average number of common shares used in net loss per share applicable to common stockholders— basic and diluted
23,402


22,579

 
23,313

 
22,479

Concert Pharmaceuticals, Inc.
Summary Balance Sheet Data
(in thousands)
 
 
June 30, 2018
 
December 31, 2017
Cash and cash equivalents
 
$
58,359

 
$
27,665

Investments, available for sale
 
121,988

 
175,500

Working capital
 
202,828

 
199,289

Total assets
 
220,515

 
211,736

Deferred revenue
 
10,533

 
10,301

Total stockholders’ equity
 
200,283

 
196,432


- more -





About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements about our expectations for clinical development of CTP-543 and CTP-692, the sufficiency of our cash, cash equivalents and investments to fund our operations and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
###


View differences made from one to another to evaluate Concert Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Concert Pharmaceuticals, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account